CTRI/2023/07/055444尚未招募2 期
AN OPEN LABELLED RANDOMISED TRIAL ON NASYA AND KARNAPOORAN WITH DHANWANTARI 101 TAILA AND SHIRODHARA WITH BILWAPACHOTYADI TAILA AND INDU VATI IN KARNANADA WITH SPECIAL REFRENCE TO TINNITUS.
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients having specific signs and symptoms of Karnanada as per Ayurvedic and modern parameters will be registered.
- •2.Tinnitus due to otological causes like Otosclerosis, Ototoxity induced Tinnitus, Noice Induced Tinnitus associated with Sensory Neural Hearing Loss will be selected.
- •3.Patients in the age group of 18-70 years.
排除标准
- •1.Patients having any congenital hearing loss or any deformity.
- •2.Tinnitus due to Systemic causes
- •3.Perforated Tympanic membrane
- •4.Psychogenic hearing loss
- •5.Patient undergone Otological surgery in past.
- •6.Infectious disease such as measels, meningitis or any TORCH infection
- •Head injury or injury to ear
- •7.Malignancy
研究者
相似试验
进行中（未招募）
不适用
A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA - SiLVERProphylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma (HCC)MedDRA version: 8.1Level: LLTClassification code 10050434EUCTR2005-005362-36-ATRegensburg University Hospital482
进行中（未招募）
不适用
A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA - SiLVERProphylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma (HCC)MedDRA version: 8.1Level: LLTClassification code 10050434EUCTR2005-005362-36-SERegensburg University Hospital482
进行中（未招募）
不适用
A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA - SiLVERProphylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma (HCC)MedDRA version: 8.1Level: LLTClassification code 10050434EUCTR2005-005362-36-GBRegensburg University Hospital482
进行中（未招募）
不适用
A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA - SiLVERProphylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma (HCC)MedDRA version: 8.1Level: LLTClassification code 10050434EUCTR2005-005362-36-FIRegensburg University Hospital482
进行中（未招募）
不适用
A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS MTOR-INHIBITOR-FREE IMMUNOSUPPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA - SILVERProphylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma HCCMedDRA version: 6.1Level: PTClassification code 10019695EUCTR2005-005362-36-ITREGENSBURG UNIVERSITY MEDICAL CENTRE525